Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an announcement.
Paradigm Biopharmaceuticals has requested a trading halt in its securities on the ASX, effective immediately, as it prepares an announcement regarding a capital raising. Trading in PAR shares will remain halted until either the capital raising announcement is released or normal trading resumes on Monday, 27 April 2026, signalling that the company is moving to secure additional funding that could influence its financial position and future development activities.
ASX Compliance confirmed the trading halt, noting Paradigm is not aware of any reason why the halt should not be granted or of any additional information required to inform the market. The move will temporarily pause trading activity and price discovery in the stock, focusing investor attention on the forthcoming capital raising details, which are likely to be material for shareholders and potential new investors.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited is an Australian biopharmaceutical company listed on the ASX under the ticker PAR, with operations in Australia, the U.S. and Ireland. The company focuses on developing pharmaceutical therapies and operates in the life sciences sector, targeting healthcare markets for its drug development programs.
Average Trading Volume: 1,212,517
Technical Sentiment Signal: Sell
Current Market Cap: A$106.2M
Find detailed analytics on PAR stock on TipRanks’ Stock Analysis page.